MARKET

IRD

IRD

Opus Genetics
NASDAQ
3.995
-0.085
-2.08%
Opening 12:18 06/24 EDT
OPEN
4.070
PREV CLOSE
4.080
HIGH
4.070
LOW
3.928
VOLUME
256.67K
TURNOVER
--
52 WEEK HIGH
5.81
52 WEEK LOW
0.9011
MARKET CAP
329.85M
P/E (TTM)
-3.0187
1D
5D
1M
3M
1Y
5Y
1D
OPUS GENETICS INC <IRD.O>: RBC INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $10
Reuters · 1d ago
Opus Genetics initiated with an Outperform at RBC Capital
TipRanks · 1d ago
U.S. RESEARCH ROUNDUP-Apogee Therapeutics, GE Healthcare, Synopsys
Reuters · 1d ago
Weekly Report: what happened at IRD last week (0615-0619)?
Weekly Report · 2d ago
Opus Genetics Is Maintained at Buy by Chardan Capital
Dow Jones · 6d ago
Opus Genetics Price Target Raised to $13.00/Share From $11.00 by Chardan Capital
Dow Jones · 6d ago
Chardan Capital Maintains Buy on Opus Genetics, Raises Price Target to $13
Benzinga · 6d ago
Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD) and Abbott Laboratories (ABT)
TipRanks · 6d ago
More
About IRD
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.

Webull offers Opus Genetics Inc stock information, including NASDAQ: IRD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IRD stock methods without spending real money on the virtual paper trading platform.